Prostate Cancer: Page 3

Higher PSA screening rates associated with less metastatic prostate cancer
By Joseph Constance
Investigators undertook a retrospective cohort study of patients to determine whether facility-level variations in PSA screening rates could be associated with subsequent facility-level metastatic prostate cancer incidence.
October 25, 2022
Mri Prostate
Veracyte announces data for prostate genomic classifier
By LabPulse.com staff writers
September 21, 2022
2021 11 01 22 15 2428 Prostate Cancer
Veracyte announces data at ESMO 2022 for prostate genomic classifier
By LabPulse.com staff writers
The data from a study presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris came from a Phase 3 trial of the multicenter, multinational, randomized STAMPEDE platform protocol. The protocol involves more than 10,000 men to date with high-risk, nonmetastatic or metastatic prostate cancer who are starting long-term androgen-deprivation therapy for the first time and are randomized to new treatments in seven Phase 3 trials.
September 11, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Veracyte to present abstracts at ESMO Congress 2022
By LabPulse.com staff writers
The following abstracts will be shared at the event in Paris on September 11:
August 30, 2022
2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400
Nanostics secures CE Mark for ClarityDx Prostate
By LabPulse.com staff writers
ClarityDx Prostate, which detects and measures extracellular vesicles, is based on a machine-learning algorithm that combines data from biological and clinical biomarkers to generate a risk score for prostate cancer that has a Gleason grade group 2 or higher on prostate biopsy.
August 22, 2022
2021 02 13 00 35 3916 Prostate Cancer 400
Genetic risk score may reduce invasive prostate biopsies
By Dexter Johnson
In research published Thursday in the British Journal of Cancer, the U.K.-based researchers calculated genetic risk for prostate cancer by leveraging more than 250 known genetic variants that are commonly linked to the disease. These genetic variants were all combined to form a single genetic risk score that could then be used to assess an individual's genetic risk of developing prostate cancer.
August 18, 2022
2022 08 19 16 39 2982 Dna Sequence Analysis 400
Deep Bio integrates DeepDx AI algorithm into Halo AP platform
By LabPulse.com staff writers
DeepDx Prostate detects prostate cancer in core needle biopsies and grades their severity based on the Gleason scoring system, according to the vendor.
August 9, 2022
2019 05 08 21 57 5547 Pathology Digital Workstation 400
MDxHealth buys Exact Sciences’ prostate cancer business
By LabPulse.com staff writers
Under the terms of an asset purchase agreement, MDxHealth paid $25 million in cash; $5 million will be settled through the delivery of 691,171 American depositary shares.
August 2, 2022
2020 03 25 23 27 0591 Hands Shaking Deal 400
miR Scientific develops molecular prostate cancer test
By LabPulse.com staff writers
miR Sentinel is a molecular test that analyzes small noncoding RNA using a biostatistical algorithm. It assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men under the age of 45 who are at risk for prostate cancer.
July 13, 2022
2021 01 08 22 20 9120 Cancer Cell Target2 400
Clinics begin adopting Genetic Technologies risk test
By LabPulse.com staff writers
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Nanostics reports study results for prostate cancer test
By LabPulse.com staff writers
The test's machine-learning algorithm combines data from two biological biomarkers and three clinical biomarkers to generate a risk score for clinically significant prostate cancer.
June 29, 2022
2019 10 16 20 31 7121 Cancer Cells Prostate 400
Indica gets CE-IVD Mark for prostate cancer screening tool
By LabPulse.com staff writers
The algorithm helps pathologists identify and grade prostate cancer from core needle biopsy samples. It was developed by researchers at the University of Cologne in Germany and was trained with more than 870,000 digital scans of prostate cancer subtypes as well as healthy tissue.
May 22, 2022
2022 05 23 20 07 1373 2022 05 23 Indica Labs Halo Prostate Ai 400
Previous Page
Page 3 of 8
Next Page